Rafarma Pharmaceuticals, Inc. (RAFA) Enters Production Agreement To Manufacture Pharmaceutical Product
Seeking Alpha Analyst Since 2008
Rafarma Pharmaceuticals announced that it entered into a production agreement last month to manufacture Para-Aminosalicylic Acid (PAS), which is to be marketed and distributed by OOO Advance Trading.
Rafarma aims to work with federal initiatives to fast track the modernization of Russia's pharmaceutical industry. It produces generic antibiotics, specialty pharmaceuticals, and its own line of proprietary products, which have been approved by the Russian Federation's Ministry of Health.
Working with Advanced Trading will allow Rafarma to increase production of PAS and to become one of the leading PAS suppliers throughout the Russian market.
As one of Russia's leading PAS distributors, Advance Trading is currently responsible for approximately 20% of sales in the Russian market. In 2011, the PAS market in Russian Federation was over than $8.2 billion dollars, according to data provided by DSM Group (a leading pharmaceutical market analyst).
Rafarma Pharmaceuticals' CEO, Dave Anderson, remarked, "This new contract is yet another expansion of Rafarma's production capability, opening the door for more revenue."
For more information, visit Rafarma.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.